Viatris (VTRS) Operating Expenses (2019 - 2026)
Viatris (VTRS) posted Operating Expenses of $1.5 billion for Q2 2026, up 17.24% on a QoQ basis from $1.2 billion in Q1 2026, and up 31.85% year-over-year from $1.1 billion in Q2 2025.
Analysis
Viatris (VTRS) Operating Expenses (2019 - 2026) Analysis & Trends
Viatris has reported Operating Expenses for 8 years, with the latest figure at $1.5 billion in Q2 2026.
- On a quarterly basis, Operating Expenses rose 31.85% year-over-year to $1.5 billion in Q2 2026; TTM through Jun 2026 was $5.2 billion, a 32.83% decrease from a year earlier, with the FY2025 full-year figure at $7.7 billion, up 36.75% from the prior year.
- Operating Expenses was $1.5 billion for Q2 2026 at Viatris, up from $1.2 billion in the prior quarter.
- The five-year high for Operating Expenses was $4.0 billion in Q1 2025, with the low at $1.1 billion in Q1 2022.
- Average Operating Expenses over 5 years is $1.5 billion, with a median of $1.2 billion recorded in 2023.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses soared 211.01% in 2025, then sank 69.41% in 2026.
- Over 5 years, Operating Expenses stood at $1.5 billion in 2022, then surged by 39.01% to $2.1 billion in 2023, then slumped by 31.99% to $1.4 billion in 2024, then declined by 3.89% to $1.3 billion in 2025, then advanced by 8.18% to $1.5 billion in 2026.
- The last three Operating Expenses figures came in at $1.5 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.61 Bn | 38.95 Bn | 2.15 Bn | 1.29 Bn |
| 2 | Viatris | 19.18 Bn | 18.30 Bn | 1.46 Bn | 1.45 Bn |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | 356.56 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | 195.34 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 518.87 Mn | 2.10 Bn | 2.11 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -65.41 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 225.58 Mn |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | 53.74 Mn |
| 9 | Fennec Pharmaceuticals | 405.56 Mn | 364.31 Mn | 17.15 Mn | 16.14 Mn |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.45 Bn |
| Mar 31, 2026 | 1.24 Bn |
| Dec 31, 2025 | 1.34 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.10 Bn |
| Mar 31, 2025 | 4.04 Bn |
| Dec 31, 2024 | 1.39 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.69 Bn |
| Mar 31, 2024 | 1.30 Bn |
| Dec 31, 2023 | 2.05 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.24 Bn |
| Mar 31, 2023 | 1.14 Bn |
| Dec 31, 2022 | 1.48 Bn |
| Sep 30, 2022 | 1.19 Bn |
| Jun 30, 2022 | 1.15 Bn |
| Mar 31, 2022 | 1.06 Bn |
| Dec 31, 2021 | 1.62 Bn |
| Sep 30, 2021 | 1.22 Bn |